Clinical Trial

Study of Readmission to Intensive Care Unit After Cardiac Surgery in Heart Hospital of Assiut University : Risk Factors .Reasons and Early Out Come

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Cardiac Surgery is any surgical procedure applied to heart and its connected vessels especially thoracic aorta; representing a treatment option for significant cardiac diseases . As cardiovascular (CVS) diseases is the first leading cause of death worldwide accounting for approximately18 million deaths annually especially in low and middle income countries , medical and surgical treatments are of importance in quality of life of cardiac patient. Most common causes for cardiac surgery are Coranary artery disease, valvular disease as mitral stenosis or mitral regurgitation, congenital heart diseases. Currently cardiac surgery can provide an advanced treatment for cardiac arrhythmias. In case of cardiovascular surgery, patient is admitted in Intensive Care Unit (ICU) postoperatively until being stable then discharged. In some cases the patient's state is indicating to be readmitted in ICU, a condition that's required long hospitzation, costs and so, a burden on health services and patient's family. For controlling this phenomenon; i.e. readmission in ICU, a lot researches were conducted to clarify the leading factors and the outcome in readmitted patients. Preoperative risk factors as renal failure, arrhythmias, chronic obstructive pulmonary disease (COPD) are common noticed factors for readmission of previous heart surgery patient. Also, readmitted patients may have poor clinical outcomes as morbidity and mortality. In this study we aim to screen for preceding risk factors and report precipitating early events occurring in readmission in ICU.
Trial Details
NCT Number NCT07083297
Lead Sponsor Assiut University
Conditions Cardiac Surgery
Enrollment 89 participants
Start Date 2025-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-24